Eko SENSORA AI Cardiac Detection Platform

Eko Health is an AI early disease detection company headquartered in Emeryville, California, led by co-founder and CEO Connor Landgraf. It targets the fact that heart valve disease, reduced heart function and atrial fibrillation are often missed during routine physical exams, because stethoscope findings depend heavily on the examiner.

Its portfolio combines ECG-enabled digital stethoscopes, ECG devices, patient and provider software and AI analysis. The SENSORA platform runs on these stethoscopes and returns assistive results in under a minute during a routine exam, flagging possible structural murmurs, low ejection fraction and atrial fibrillation so clinicians can refer patients for echocardiography sooner. The company also offers telehealth and integration options for health systems, and sells to hospitals, primary care practices and public health agencies, with more than 650,000 devices sold to providers globally.

• Digital stethoscopes: ECG-enabled devices capture heart sounds and ECG during routine exams.
• Murmur detection: AI flags possible structural heart murmurs for valve disease workup.
• Low EF detection: AI identifies signs of reduced ejection fraction from a single auscultation point.
• AFib detection: AI analysis of the ECG flags possible atrial fibrillation.
• Fast results: assistive insights are returned in under a minute at the point of care.
• Health system tools: patient and provider software, telehealth options and integrations.

District hospitals and commune health stations in Vietnam could screen elderly patients for valve disease and heart failure before referring them for echocardiography. Corporate health check providers could add AI-assisted auscultation to annual examinations. Telehealth providers could pair digital stethoscopes with remote cardiology consultations.

Helps primary care and emergency clinicians detect hidden heart disease during a normal exam, with results in under a minute. In a Circulation study cited by Eko, murmur detection sensitivity was 90% versus 43% for standard auscultation. A Lancet Digital Health study reported 85% sensitivity and 70% specificity for low ejection fraction from a single auscultation point. A dedicated CPT code supports reimbursement in the US.

Payers and regulators are starting to reimburse AI-assisted diagnostics, moving point-of-care AI from pilots into routine practice. Across Asia, where echocardiography and cardiologists are scarce outside cities, AI screening at the primary care level is seen as a way to find structural heart disease and heart failure earlier.

Headquartered in Emeryville, California, USA; co-founder and CEO Connor Landgraf, with Dr. Steven Steinhubl chairing the Clinical Advisory Board. More than 650,000 devices sold to providers globally. SENSORA is FDA-cleared and received an AMA Category III CPT code effective July 2025.